Peptide Comparison
CJC-1295 vs Sermorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRHs in the same regimen: Moderate risk per peptide research literature. Same receptor: competition at pituitary GHRH receptor; no additive benefit, reduced efficiency.
Data-derived verdict
CJC-1295 and Sermorelin share the ghrh / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| CJC-1295 | Sermorelin | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | GHRH analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release |
| Route | SC injection | SC injection |
| Half-life | No-DAC ~30 min / DAC ~8 days | ~10-20 min |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | 200-500 mcg SC at bedtime daily |
| Evidence tier | Anecdotal + Phase 2 (DAC) | Discontinued (FDA approval 1990; US withdrawal 2008) |
| Research depth | 57 indexed | 247 indexed |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Injection site reactions; headache; flushing |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or Sermorelin?
CJC-1295 and Sermorelin share the ghrh / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.
What is the difference between CJC-1295 and Sermorelin?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Sermorelin is classed as GHRH analog. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Sermorelin, ~10-20 min. Routes in published studies: CJC-1295, SC injection; Sermorelin, SC injection.
Which has stronger evidence, CJC-1295 or Sermorelin?
CJC-1295 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 57 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 247 indexed studies.
Which is more accessible, CJC-1295 or Sermorelin?
Neither CJC-1295 nor Sermorelin is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; Sermorelin, Compounding Restricted. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are CJC-1295 and Sermorelin ever combined?
CJC-1295 and Sermorelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRHs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…